Relapsing Multiple Sclerosis Cognition
Protocol: STUDY00004063
Full Title
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod
Description
This study enrolls adults with Relapsing Multiple Sclerosis. The purpose of this study is to learn about changes in cognition that happen while being treated with the experimental medication RPC1063 (also known as ozanimod).

You will be in this study for about 40 months altogether. You will come for clinic visits about every 3 months. At different points during the study you will have physical and neurological examinations, have your blood taken, and have EKGs and MRIs done. You will also complete surveys and have some cognitive testing done. All of these things will be done yearly. You will also be given the investigational drug. Study takes place at UBMD Neurology locations in Buffalo, NY.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
- Adults ages 18-65.
- Have at least 5 years since time of RMS diagnosis.
- Have no clinically relevant cardiovascular conditions.
Age Group: Adults
Principal Investigator: BIANCA WEINSTOCK-GUTTMAN
ClinicalTrials.gov: Open Study
Contact(s)
KARA PATRICK
kpatrick@buffalo.edu
+1 716-829-5037
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.